A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Olgotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Zhejiang ACEA Pharmaceutical
Most Recent Events
- 12 Sep 2023 Primary endpoint (Time from the first dose to sustained recovery from 11 target symptoms of COVID-19.) has been met, according to a Sorrento Therapeutics media release.
- 12 Sep 2023 Positive top-line results presented in a Sorrento Therapeutics Media Release.
- 26 Jun 2023 According to a Sorrento Therapeutics media release, the company look forward to seeing the final data and to working closely with the NMPA during the review to evaluate this as a potential stand-alone treatment for COVID-19 patients as rapidly as possible.